Table 1 Main characteristics of the studies included in meta-analysis
Study | Study design | Study period | Publication type | Region | Setting | Regimen | Duration (weeks) | Daily dose of LDV/SOF |
|---|---|---|---|---|---|---|---|---|
Akiyama et al. [33] | Randomized trial | NA | Abstract | Sub-Saharan Africa | Multi-center | LDV/SOF | NA | NA |
Akiyama et al.[34] | Randomized trial | 2013.10–2017.4 | Full-length | New York | Multi-center | LDV/SOF | 4/8/12 | NA |
Gayam et al. [23] | Retrospective cohort study | 2016.1–2017.12 | Full-length | America | Multi-center | LDV/SOF ± RBV | NA | NA |
Alimohammadi et al. [24] | Retrospective study | 2015.9–2019.2 | Full-length | Canada | Multi-center | LDV/SOF | NA | NA |
Coffin et al. [25] | Two-arm randomized trial | 2015–2017 | Full-length | San Francisco | Single-center | LDV/SOF | 8 | 80/400 mg |
Schütz et al.[26] | Observational study | 2015.9–2016.9 | Full-length | Austria | Multi-center | LDV/SOF | 8 | 90/400 mg |
Øvrehus et al.[27] | Randomized trial | 2015.4–2016.4 | Full-length | Denmark | Single-center | LDV/SOF/RBV ± PEG | 4 | 90/400 mg |
Trabut et al. [28] | Retrospective case–control study | NA | Full-length | French | Multi-center | LDV/SOF ± RBV | 8/12 | NA |
Grebely et al.[29] | Randomized trial | 2012.10–2016.5 | Full-length | 6 Study locations | Multi-center | LDV/SOF ± RBV | 8/12/24 | 90/400 mg |
Morris et al. [30] | Observational study | 2016.3–2017.2 | Full-length | Australia | Single-center | LDV/SOF | 8/12/24 | NA |
Read et al. [31] | Observational cohort study | 2015–2017 | Full-length | Australia | Single-center | LDV/SOF | 8/12/24 | NA |
Grebely et al. [32] | Randomized trial | 2013.11–2014.4 | Full-length | 88 study locations | Multi-center | LDV/SOF ± RBV | 8/12/24 | 90/400 mg |